A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Trial Profile

A Double-blind, Placebo-Controlled, Randomized Withdrawal Following Open Label Therapy Study to Assess the Safety and Efficacy of Levoketoconazole (2S, 4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs Levoketoconazole (Primary)
  • Indications Cushing syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms LOGICS
  • Sponsors Strongbridge Biopharma
  • Most Recent Events

    • 14 Nov 2017 According to a company media release, Strongbridge anticipates enrollment of the first patient in this study in the fourth quarter of 2017. Top-line results from this trial are expected in the fourth quarter of 2018.
    • 11 Sep 2017 Planned End Date changed from 1 Dec 2018 to 1 Jul 2018.
    • 11 Sep 2017 Planned primary completion date changed from 30 Aug 2018 to 30 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top